<img src="https://ml.globenewswire.com/Resource/Download/908fb457-7f8e-4a08-9081-5565e3dfb3d7?size=2" nborder="0" align="left" hspace="5" vspace="5" title="22157.jpg" alt="Company Logo"/>CD137 oncology pipelines are expanding, led by bispecific platforms and combination therapies targeting solid tumors, improved efficacy and reduced toxicity.Dublin, Sept. 16, 2026 <a href="https://www.globenewswire.com" target="_blank">(GLOBE NEWSWIRE)</a> -- <a href="https://www.researchandmarkets.com/reports/6216442/cd137-targeted-therapy-market-opportunity?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=r8nl4w&amp;utm_campaign=2350564+-+CD137-Targeted+Therapy+Market+Set+for+Growth+as+Novel+Therapeutic+Approaches%2c+Advanced+Technology+Platforms+and+Expanding+Clinical+Trials+Unlock+New+Opportunities+Through+2026&amp;utm_exec=clshmsai" rel="nofollow" target="_blank" title="CD137 Targeted Therapy Market Opportunity, Therapeutic Approaches, Technology Development Platforms &amp; Clinical Trials Insight 2026">"CD137 Targeted Therapy Market Opportunity, Therapeutic Approaches, Technology Development Platforms &amp; Clinical Trials Insight 2026"</a> has been added to ResearchAndMarkets.com's offering. Report Highlights <ul><li>First commercial launch of a CD137-targeted therapy expected by 2030</li><li>Analysis of more than 90 CD137-targeted therapies in clinical development</li><li>Clinical trial insights by company, country, indication and development phase</li><li>Pipeline development extending through Phase III clinical trials</li><li>Assessment of proprietary CD137-targeted therapy technology platforms</li><li>Evaluation of global and regional clinical and commercial trends</li><li>Review of therapeutic approaches designed to target CD137</li></ul> Growing Need for CD137-Targeted Therapies CD137, also known as 4-1BB, is a co-stimulatory receptor involved in T-cell activation, survival and expansion. Its capacity to enhance antitumor immune responses has established CD137 as an important target in cancer immunotherapy research. Despite substantial advances in immuno-oncology, chemotherapy, immune checkpoint inhibitors and other established treatments continue to demonstrate limitations in efficacy, durability and patient response, particularly in several solid tumor indications. CD137-targeted therapies are being investigated for their potential to stimulate immune activity within the tumor microenvironment and strengthen antitumor responses. The report examines the expanding CD137-targeted therapies market and pipeline, covering ongoing clinical trials, emerging therapeutic approaches, proprietary technology platforms and the companies driving innovation. It also evaluates the scientific, clinical and competitive factors expected to influence the future commercialization of CD137-targeted treatments. CD137-Targeted Therapies Clinical Trial Analysis The report provides a detailed assessment of more than 90 CD137-targeted therapies across multiple stages of clinical development. Clinical trial analysis is segmented by company, country, indication and phase, with the most advanced programs reaching Phase III. The pipeline includes programs targeting solid tumors and hematological malignancies, offering stakeholders a comprehensive view of current research priorities and development activity. Combination treatment strategies represent a significant area of clinical investigation. CD137 agonists and related agents are being evaluated alongside chemotherapy, immune checkpoint inhibitors and targeted treatments, including PD-1 and VEGF inhibitors. These studies are designed to determine whether combination regimens can improve response rates, treatment durability and clinical outcomes compared with monotherapy. The report reviews emerging safety and efficacy findings, development challenges and evidence shaping future clinical strategies. Proprietary Technology Platforms Technology innovation is central to the development of next-generation CD137-targeted therapies. The report profiles proprietary platforms intended to increase tumor selectivity, enhance therapeutic activity and reduce systemic toxicity. Among the featured technologies is AP Biosciences' T-cube platform, which supports the development of bispecific antibodies designed to activate CD137-mediated T-cell responses following engagement with tumor-associated antigens. These platforms may help address safety concerns associated with immune activation, including cytokine release and off-target effects. The report assesses the strategic importance of bispecific antibodies, targeted delivery systems and other emerging modalities within the evolving CD137-targeted therapy pipeline. Leading Companies Developing CD137-Targeted Therapies The competitive landscape includes established pharmaceutical companies and emerging biotechnology developers. Roche, Genmab and Sichuan Baili Pharmaceutical are among the companies advancing CD137-targeted candidates through clinical development. ABL Bio, Pieris Pharmaceuticals and other specialized biotechnology companies are contributing additional innovation through bispecific antibody formats, differentiated delivery technologies and novel combination strategies. The report profiles leading participants, pipeline assets, clinical progress, research partnerships and development strategies. This analysis provides insight into competitive positioning and the organizations expected to shape the global CD137-targeted therapies market. Future Outlook for the CD137-Targeted Therapies Market The first commercial launch of a CD137-targeted therapy is expected by 2030, supported by continued clinical progress and investment in next-generation immuno-oncology platforms. Future development is likely to focus on improving tumor-specific immune activation, overcoming immune resistance and reducing adverse events such as cytokine release syndrome. Combination regimens involving CD137 agonists, checkpoint inhibitors and targeted therapies could become increasingly important as new clinical evidence emerges. By examining clinical, technological, competitive and commercial trends, the report enables pharmaceutical companies, biotechnology developers, investors and other stakeholders to assess opportunities and anticipate the future direction of the global CD137-targeted therapies landscape. Key Topics Covered: 1. Research Methodology 2. Brief Introduction to CD137 2.1 Clinical Overview 2.2 Biological History of CD137 2.3 CD137 Hosting an Era of Agonists Over Antagonists 2.4 Bi-Directional Signaling in CD137 3. Global CD137 Targeted Therapy Market Outlook 3.1 Current Research &amp; Market Scenario 3.2 Future Commercialization Opportunities 4. CD137 Targeted Therapy Clinical Innovation Trends by Region 4.1 China 4.2 South Korea 4.3 US 4.4 Europe 4.5 Australia 5. CD137 Role &amp; Clinical Progress by Indication 5.1 Cancer 5.1.1 Leukemia 5.1.2 Lymphoma 5.1.3 Lung Cancer 5.1.4 Melanoma 5.1.5 Breast Cancer 5.1.6 Colorectal Cancer 5.2 Autoimmune &amp; Inflammatory Diseases 5.3 Microbial Infections 5.4 Neuronal Diseases 6. Global CD137 Targeted Therapies Clinical Trials Overview 6.1 by Company 6.2 by Country 6.3 by Indication 6.4 by Phase 7. CD137 Targeted Therapies Clinical Trials Insight by Company, Country, Indication &amp; Phase 7.1 Research 7.2 Preclinical 7.3 Phase I 7.4 Phase I/II 7.5 Phase II 7.6 Phase III 8. CD137 Targeted Therapy Proprietary Technology Platforms by Companies 9. Therapeutic Approaches for Targeting CD137 9.1 Antibodies 9.1.1 Monoclonal antibodies 9.1.2 Bispecific Antibody Centered Approaches 9.1.3 Trispecific Antibody Established Strategies 9.1.4 Tetraspecific Antibody Strategies 9.1.5 Single-chain variable fragments 9.2 Peptides 9.3 Protein-Based Therapeutics 10. Combination Therapies with CD137 Targeted Therapy 11. Competitive Landscape 11.1 ABL Bio 11.2 Adagene 11.3 Alligator Bioscience 11.4 BeOne Medicines 11.5 Bicycle Therapeutics 11.6 BioNTech 11.7 Crescendo Biologics 11.8 Compass Therapeutics 11.9 Eutilex 11.10 F-star Therapeutics 11.11 Genmab 11.12 NovaBridge Biosciences 11.13 Kyinno Biotechnology 11.14 Lyvgen Biopharma 11.15 Obsidian Therapeutics 11.16 OriCell Therapeutics 11.17 Palvella Therapeutics 11.18 Shanghai Henlius Biotech 11.19 Sichuan Baili Pharmaceutical 11.20 SystImmune List of Tables Table 2-1: CD137 Expression Across Cell Types Table 2-2: Comparison of Antagonistic vs Agonistic Immunotherapies Table 5-1: Lymphoma - Clinical Trials Underway for GNC-038 &amp; GNC-035 Table 9-1: Some Bispecific Antibodies Targeting CD137 in Development Table 9-2: Some Trispecific Antibodies Targeting CD137 in Development Table 9-3: Some Tetraspecific Antibodies Targeting CD137 in Development Table 10-1: Ongoing Clinical Trials Evaluating CD137 Antibody Combinations List of Figures Figure 2-1: Evolution of Cancer Immunotherapy Approaches Figure 2-2: Biological Effects Triggered by CD137 Stimulation Figure 2-3: CD137 - Discovery &amp; Early Biological Characterization Figure 2-4: Mechanistic Pathways Triggered by CD137 Ligation Figure 2-5: Anti-CD137 Monoclonal Antibody - Immune Regulation Mechanisms Figure 2-6: Why CD137 Became An Important Target Figure 2-7: Schematic Depiction of Bidirectional Signaling by CD137-CD137L Figure 2-8: CD137 - Forward Signaling Cascade in Immune Cells Figure 2-9: CD137L - Reverse Signaling Figure 2-10: Bidirectional Signaling Loop Between CD137 &amp; CD137L Figure 3-1: Global CD137 Targeting Therapy Market - Future Opportunities Figure 5-1: Bidirectional CD137-CD137L Signaling in Leukemia Cell Survival Figure 5-2: GNC-035-105 Phase Ib/II (NCT05944978) Study - Initiation &amp; Completion Year Figure 5-3: GNC-035-105 Phase I (NCT05944978) Study - Initiation &amp; Completion Year Figure 5-4: GNC-038-101 Phase I (NCT04606433) Study - Initiation &amp; Completion Year Figure 5-5: Lymphoma - CD137's Role in Countering Immune Evasion Figure 5-6: BP41072 Phase I/II (NCT04077723) Study - Initiation &amp; Completion Year Figure 5-7: YH004003 Phase I (NCT05564806) Study - Initiation &amp; Completion Year Figure 5-8: IBD0333-101 Phase I/II (NCT06292208) Study - Initiation &amp; Completion Year Figure 5-9: Lung Cancer - Rationale for Targeting CD137 Figure 5-10: BT7480-100 Phase I/II (NCT05163041) Study - Initiation &amp; Completion Year Figure 5-11: GCT1046-04 Phase 2 (NCT05117242) Study - Initiation &amp; Completion Year Figure 5-12: HLX35-FIH101 Phase I (NCT05360381) Study - Initiation &amp; Completion Year Figure 5-13: EU-CTS101-I-01 Phase I/II (NCT04903873) Study - Initiation &amp; Completion Year Figure 5-14: Melanoma - CD137 as a Costimulatory Driver of Disease Immunity Figure 5-15: FS222-19101 Phase I (NCT04740424) Study - Initiation &amp; Completion Year Figure 5-16: LBL-024-CN007 Phase I/II (NCT07099430) Study - Initiation &amp; Completion Year Figure 5-17: ABBIL1TY MELANOMA-07 Phase II (NCT06984328) Study - Initiation &amp; Completion Year Figure 5-18: Breast Cancer - Dual Role of CD137 in Disease Biology Figure 5-19: BT7480-100 Phase I/II (NCT05163041) Study - Initiation &amp; Completion Year Figure 5-20: AP402-101 Phase I/II (NCT06669975) Study - Initiation &amp; Completion Year Figure 5-21: AVIATOR Phase 2 (NCT03414658) Study - Initiation &amp; Completion Year Figure 5-22: ADG106-T6002 Phase 1/2 (NCT05275777) Study - Initiation &amp; Completion Year Figure 5-23: YH32367-101 Phase I/II (NCT05523947) Study - Initiation &amp; Completion Year Figure 5-24: GNC-035-103 Phase I (NCT05160545) Study - Initiation &amp; Completion Year Figure 5-25: EU-CTS101-I-01 Phase I/II (NCT04903873) Study - Initiation &amp; Completion Year Figure 5-26: NCI-2018-01036 Phase 1 (NCT03290937) Study - Initiation &amp; Completion Year Figure 5-27: 1002-CL-0101 Phase I (NCT05719558) Study - Initiation &amp; Completion Year Figure 5-28: BNT314-02 Phase I/II (NCT07079631) Study - Initiation &amp; Completion Year Figure 5-29: CD137 - Dual Role in Immune Regulation Figure 5-30: Microbial Infections - CD137 Expression &amp; Immune Roles Figure 5-31: CD137 in Neuroinflammation Figure 6-1: Global - CD137 Targeted Therapies Clinical Pipeline by Company (Numbers), 2026 Figure 6-2: Global - CD137 Targeted Therapies Clinical Pipeline by Country (Numbers), 2026 Figure 6-3: Global - CD137 Targeted Therapies Clinical Pipeline by Indication (Numbers), 2026 Figure 6-4: Global - CD137 Targeted Therapies Clinical Pipeline by Phase (Numbers), 2026 Figure 8-1: Adagene - Anti CD137 NEObody ACG106 Figure 8-2: Adagene - Anti CD137 POWERbody ADG206 Figure 8-3: Genmab - DUObody Production Process Figure 8-4: Genmab - DUObody Platform Detail Figure 8-5: Crescendo Biologics - Humabody Structure Figure 8-6: CB307 Humabody - Structure Figure 8-7: Numab Therapeutics - MATCH Format Figure 8-8: NM21-1480 - Structure Figure 8-9: Systimmune - GNC-039 Structure Figure 8-10: Systimmune - GNC-035 Structure Figure 8-11: Systimmune - GNC-038 Structure Figure 8-12: Merus - Multiclonics Structure Figure 8-13: Chugai Pharmabody Research - Dual-Ig Technology Figure 8-14: Eutilex - Costim Platform Technology Figure 8-15: aND-Body - Ampersand Biomedicines Figure 8-16: X-body Platform - Leads Biolabs Figure 8-17: T-cube Bispecific Antibody Platform - AP Biosciences Figure 8-18: Grabody-T - ABL Bio Figure 8-19: LEAD-452 Trimerbody - Structure Figure 9-1: ATOR-1017 - Mechanism of Action Figure 9-2: EU101 - Mode of Action Figure 9-3: LVGN6051 - Mechanism of Action Figure 9-4: Ragistomig - Structure &amp; Mechanism of Action Figure 9-5: FS120 - Improving PD-1 &amp; Chemotherapy Responses Figure 9-6: FS222 - Structure Figure 9-7: FS222 - Mechanism of Action Figure 9-8: MP0310 - Mechanism of Action Figure 9-9: CD137 Targeting GNC Tetraspecific Antibodies Figure 9-10: CD137 Targeting Peptide - Mechanism Figure 9-11: CD137 Targeting Fusion Protein - Conditional Activation Design A selection of companies mentioned in this report includes, but is not limited to: <ul><li>ABL Bio</li><li>Adagene</li><li>Alligator Bioscience</li><li>BeOne Medicines</li><li>Bicycle Therapeutics</li><li>BioNTech</li><li>Compass Therapeutics</li><li>Crescendo Biologics</li><li>Eutilex</li><li>F-star Therapeutics</li><li>Genmab</li><li>Kyinno Biotechnology</li><li>Lyvgen Biopharma</li><li>NovaBridge Biosciences</li><li>Obsidian Therapeutics</li><li>OriCell Therapeutics</li><li>Palvella Therapeutics</li><li>Shanghai Henlius Biotech</li><li>Sichuan Baili Pharmaceutical</li><li>SystImmune</li></ul> For more information about this report visit <a href="https://www.researchandmarkets.com/reports/6216442/cd137-targeted-therapy-market-opportunity?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=r8nl4w&amp;utm_campaign=2350564+-+CD137-Targeted+Therapy+Market+Set+for+Growth+as+Novel+Therapeutic+Approaches%2c+Advanced+Technology+Platforms+and+Expanding+Clinical+Trials+Unlock+New+Opportunities+Through+2026&amp;utm_exec=clshmsai" rel="nofollow" target="_blank" title="">https://www.researchandmarkets.com/r/x2s776</a> About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. <pre>CONTACT: 
CONTACT: ResearchAndMarkets.com 
 Laura Wood,Senior Press Manager 
 press@researchandmarkets.com
 For E.S.T Office Hours Call 1-917-300-0470 
 For U.S./ CAN Toll Free Call 1-800-526-8630 
 For GMT Office Hours Call +353-1-416-8900 

</pre> <img alt="" src='https://ml.globenewswire.com/media/NzUwZDU2YjYtOTJiMi00NGFkLWFhMGYtZmMwMTAzYzNlMWIyLTEwMjY3MzctMjAyNi0wOS0xNi1lbg==/tiny/Research-and-Markets.png' referrerpolicy='no-referrer-when-downgrade' />

CD137-Targeted Therapy Market Set for Growth as Novel Therapeutic Approaches, Advanced Technology Platforms and Expanding Clinical Trials Unlock New Opportunities Through 2026

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn